Ceribell Q2 revenue beats estimates; raises 2026 revenue outlook
Ceribell Q2 revenue beats estimates; raises 2026 revenue outlook
Overview
US medical device maker's Q2 revenue rose 33% yr/yr, beating analyst expectations
Q2 net loss and loss per share were wider than analyst estimates
Gross margin improved to 92% on cost reductions and one-time tariff refund
Outlook
Ceribell raises 2026 revenue guidance to $114 mln-$117 mln
Company expects continued momentum from new account additions and increased utilization
NTAP for delirium monitoring solution to become effective October 1, 2026
Result Drivers
ACCOUNT GROWTH AND UTILIZATION - Co said revenue increase was driven by new account additions and higher utilization among existing customers, despite seasonal moderation in ICU census
COST REDUCTIONS AND TARIFF REFUNDS - Gross margin improvement attributed to manufacturing cost reduction initiatives, new Vietnam manufacturing line, and a one-time benefit from tariff refunds
SUBSCRIPTION BASE EXPANSION - Subscription revenue rose on continued growth in installed base of Clarity subscriptions
Company press release: ID:nGNXTdvBq
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $28.10 mln | $27.29 mln (8 Analysts) |
Q2 Loss Per Share | Miss | $0.51 | $0.47 (8 Analysts) |
Q2 Net Loss | Miss | $19.30 mln | $17.95 mln (7 Analysts) |
Q2 Gross Profit |
| $25.90 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for CeriBell, Inc. is $26.00, about 38.2% above its August 7 closing price of $18.81
Reuters Recommended Reads
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Aug 10 - Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)